Louise Frederika Kooij
Known title: Chief Accounting OfficerCIK: 0002004379
Associated companies
Transaction History
| NAMS | ▲ Buy | Option Exercise | 25,000 | $298K | 7/20/2026 | View on chart |
| NAMS | ▲ Buy | Option Exercise | 80,000 | $894K | 7/20/2026 | View on chart |
| NAMS | ▼ Sell | Open Market | 70,200 | $2.1M | 7/20/2026 | View on chart |
| NAMS | ▼ Sell | Open Market | 31,885 | $990K | 7/20/2026 | View on chart |
| NAMS | ▼ Sell | Open Market | 2,915 | $92K | 7/20/2026 | View on chart |
| NAMS | ▲ Buy | Option Exercise | 25,000 | $273K | 6/22/2026 | View on chart |
| NAMS | ▲ Buy | Option Exercise | 15,000 | $179K | 6/22/2026 | View on chart |
| NAMS | ▼ Sell | Open Market | 39,700 | $1.2M | 6/22/2026 | View on chart |
| NAMS | ▼ Sell | Open Market | 300 | $9K | 6/22/2026 | View on chart |
| NAMS | ▲ Buy | Option Exercise | 60,000 | $600K | 5/26/2026 | View on chart |
| NAMS | ▲ Buy | Option Exercise | 5,000 | $55K | 5/26/2026 | View on chart |
| NAMS | ▼ Sell | Open Market | 65,000 | $2.3M | 5/26/2026 | View on chart |
| NAMS | ▼ Sell | Open Market | 32,612 | $1.0M | 1/28/2026 | View on chart |
| NAMS | ▲ Buy | Option Exercise | 32,612 | $355K | 1/28/2026 | View on chart |
| NAMS | ▲ Buy | Option Exercise | 39,816 | $434K | 1/27/2026 | View on chart |
| NAMS | ▼ Sell | Open Market | 39,816 | $1.3M | 1/27/2026 | View on chart |
| NAMS | ▲ Buy | Option Exercise | 34,400 | $375K | 1/26/2026 | View on chart |
| NAMS | ▼ Sell | Open Market | 34,091 | $1.1M | 1/26/2026 | View on chart |
| NAMS | ▼ Sell | Open Market | 309 | $10K | 1/26/2026 | View on chart |
| NAMS | ▲ Buy | Option Exercise | 38,172 | $416K | 1/23/2026 | View on chart |
| NAMS | ▼ Sell | Open Market | 25,405 | $850K | 1/23/2026 | View on chart |
| NAMS | ▼ Sell | Open Market | 12,767 | $439K | 1/23/2026 | View on chart |
| NAMS | ▲ Buy | Grant | 12,000 | — | 1/7/2026 | View on chart |
| NAMS | ▼ Sell | Open Market | 2,647 | $88K | 1/5/2026 | View on chart |
| NAMS | ▲ Buy | Option Exercise | 38,872 | $389K | 12/26/2025 | View on chart |
| NAMS | ▲ Buy | Option Exercise | 5,000 | $55K | 12/26/2025 | View on chart |
| NAMS | ▼ Sell | Open Market | 43,872 | $1.5M | 12/26/2025 | View on chart |
| NAMS | ▲ Buy | Option Exercise | 26,011 | $260K | 12/24/2025 | View on chart |
| NAMS | ▼ Sell | Open Market | 26,011 | $928K | 12/24/2025 | View on chart |
| NAMS | ▲ Buy | Option Exercise | 75,117 | $751K | 12/23/2025 | View on chart |
| NAMS | ▼ Sell | Open Market | 75,117 | $2.7M | 12/23/2025 | View on chart |
| NAMS | ▲ Buy | Option Exercise | 150,000 | $1.5M | 9/9/2025 | View on chart |
| NAMS | ▼ Sell | Open Market | 53,104 | $1.3M | 9/9/2025 | View on chart |
| NAMS | ▼ Sell | Open Market | 96,896 | $2.5M | 9/9/2025 | View on chart |
| NAMS | ▼ Sell | Open Market | 18,073 | $453K | 9/3/2025 | View on chart |
| NAMS | ▲ Buy | Option Exercise | 18,073 | — | 9/2/2025 | View on chart |
| NAMS | ▼ Sell | Open Market | 8,269 | $206K | 8/25/2025 | View on chart |
| NAMS | ▲ Buy | Option Exercise | 8,269 | $0 | 3/26/2025 | View on chart |
| NAMS | ▲ Buy | Option Exercise | 150,000 | — | 3/4/2025 | View on chart |
| NAMS | ▼ Sell | Open Market | 150,000 | $3.1M | 3/4/2025 | View on chart |
| NAMS | ▲ Buy | Grant | 15,000 | — | 1/7/2025 | View on chart |
| NAMS | ▼ Sell | Open Market | 45,000 | $707K | 10/1/2024 | View on chart |
| NAMS | ▲ Buy | Option Exercise | 45,000 | — | 9/27/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
RBC Capital Lowers Target to $42 for NAMS
RBC Capital has kept its outperform rating for NewAmsterdam Pharma (NAMS) but cut its price target to $42. The new target sits at the top of the 52‑week range and near the current support level of $35.04. The stock’s RSI of 33.5 suggests it is in an oversold zone, which may influence short‑term trading activity. Analysts still see upside potential, but the lowered target reflects a more cautious outlook.
RBC Capital Lowers Target to $42 for NAMS. RBC Capital has kept its outperform rating for NewAmsterdam Pharma (NAMS) but cut its price target to $42. The new target sits at the top of the 52‑week range and near the current support level of $35.04. The stock’s RSI of 33.5 suggests it is in an oversold zone, which may influence short‑term trading activity. Analysts still see upside potential, but the lowered target reflects a more cautious outlook.